| Product Name | ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML |
| Active Ingredient (Strength) | Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml) |
| Application type | NDA-2: New formulation / strength |
| Product Registrant | AGUETTANT ASIA PACIFIC PTE. LTD. |
| Date of Approval | 07/11/2023 |
| Registration No. | SIN16897P |
| Indications: – Cardiopulmonary resuscitation – Acute anaphylaxis in adults | |
| Product Name | AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL |
| Active Ingredient (Strength) | Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial) |
| Application type | NDA-1: New chemical entity |
| Product Registrant | JUNIPER BIOLOGICS PTE LTD |
| Date of Approval | 28/11/2023 |
| Registration No. | SIN16899P |
| Indications: AKYNZEO IV is indicated in adults for the: – Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy, including cisplatin. – Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. | |
| Product Name | LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION |
| Active Ingredient (Strength) | Gozetotide (25μg/vial) |
| Application type | NDA-1: New chemical entity |
| Product Registrant | NOVARTIS (SINGAPORE) PTE LTD |
| Date of Approval | 30/11/2023 |
| Registration No. | SIN16904P |
| Indications: Locametz, after radiolabelling with gallium-68, is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings: · Primary staging of patients with high-risk PCa prior to primary curative therapy, · Suspected PCa recurrence in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy, · Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated. | |
| Product Name | TRAZHER (TRASTUZUMAB) POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/VIAL |
| Active Ingredient (Strength) | Trastuzumab (420 mg/vial) |
| Application type | NDA-3: New pack size |
| Product Registrant | INNOGENE KALBIOTECH PTE. LTD. |
| Date of Approval | 22/11/2023 |
| Registration No. | SIN16898P |
| Indications: Trazher IV Metastatic Breast Cancer (MBC) Trazher is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress HER2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease b) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease c) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer, not previously treated with Trazher. This indication is based on data from one Phase III trial which studied the use of Trazher in combination with anastrozole (see Clinical/ Efficacy Studies). Experience with other aromatase inhibitors is limited. Early Breast Cancer (EBC) Trazher is indicated for the treatment of patients with HER2 positive early breast cancer. – following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see Clinical/ Efficacy Studies). – following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.- in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. – in combination with neoadjuvant chemotherapy followed by adjuvant Trazher therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter (see Special Warnings and Precautions for Use, and Clinical/ Efficacy Studies). Trazher should only be used in patients whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay. Metastatic Gastric Cancer (MGC) Trazher in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Trazher should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, as determined by an accurate and validated assay. | |
HSA: Health Sciences Authority
Link to the HSA announcement: https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals—november-2023
Only Authentic Products and Genuine Medical Supplies, at POM Marketplace!
Login or Register now to access our comprehensive range of medical supplies.
Disclaimer: The information provided on this page is intended solely for healthcare professionals for informational purposes only. While we strive for accuracy, POMConnect assumes no liability for errors or omissions. The content here should not be considered a substitute for professional medical advice. POMConnect does not endorse specific treatments or external websites linked from this page. Please note that the information is accurate at the time of publication and does not account for any modifications or updates made to the original research article after its initial publish date. POM Marketplace is accessible to qualified healthcare professionals only. Any unauthorized access or use by individuals who do not meet this criteria is prohibited.
